BOSTON and SOUTH SAN FRANCISCO, Calif. (August 28, 2025) – Frontier Medicines Corporation, a clinical-stage precision medicine company unlocking the proteome to develop small molecule precision oncology medicines against otherwise undruggable disease-causing targets, today announced that members of its leadership team will participate in two upcoming investor conferences:

• Citi 2025 Biopharma Back to School Conference, September 2, 2025
• Bank of America Healthcare Trailblazers Private Company Conference, September 17, 2025

An updated corporate presentation, if available, will be made available on the “Newsroom” page of the Frontier Medicines website.

About Frontier Medicines
Frontier Medicines is a clinical-stage precision medicine company pioneering groundbreaking medicines to transform treatment for genetically defined patient populations, starting with oncology and immunology. Our proprietary chemoproteomics-powered drug discovery engine, the Frontier™ Platform, leverages covalent chemistry and machine learning to unlock hard-to-treat disease-causing proteins for drug development. Today, we are advancing a diversified pipeline of wholly owned precision medicines against the most critical drivers of cancer and high-value immunology programs. For more information, please visit www.frontiermeds.com. Follow Frontier on LinkedIn.